Publications by Hong Yang
Peer reviewed
Articles
[1]
M. Shi et al., "A resource for whole-body gene expression map of human tissues based on integration of single cell and bulk transcriptomics," Genome Biology, vol. 26, no. 1, 2025.
[2]
S. Soleimani et al., "Cellular and immune landscape of chronic liver diseases : insights from immunophenotyping," Frontiers in Molecular Biosciences, vol. 11, 2025.
[3]
H. Yang et al., "Integrative proteo-transcriptomic characterization of advanced fibrosis in chronic liver disease across etiologies," Cell Reports Medicine, vol. 6, no. 2, 2025.
[4]
B. Yulug et al., "Multi-omics characterization of improved cognitive functions in Parkinson’s disease patients after the combined metabolic activator treatment : a randomized, double-blinded, placebo-controlled phase II trial," Brain Communications, vol. 7, no. 1, 2025.
[5]
H. Yang et al., "Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in rats," eLIFE, vol. 13, 2025.
[6]
X. Song et al., "Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort," PLOS Genetics, vol. 21, no. 7 July, 2025.
[7]
M. Yuan et al., "The Human Pathology Atlas for deciphering the prognostic features of human cancers," EBioMedicine, vol. 111, 2025.
[8]
J. Baudin et al., "A cocktail of histidine, carnosine, cysteine and serine reduces adiposity and improves metabolic health and adipose tissue immunometabolic function in ovariectomized rats," Biomedicine and Pharmacotherapy, vol. 179, 2024.
[9]
F. Bonanini et al., "A comparison between different human hepatocyte models reveals profound differences in net glucose production, lipid composition and metabolism in vitro," Experimental Cell Research, vol. 437, no. 1, 2024.
[10]
Ö. Altay et al., "Combined Metabolic Activators with Different NAD+ Precursors Improve Metabolic Functions in the Animal Models of Neurodegenerative Diseases," Biomedicines, vol. 12, no. 4, 2024.
[11]
S. Snanoudj et al., "Genome-wide expression analysis in a Fabry disease human podocyte cell line," Heliyon, vol. 10, no. 14, 2024.
[12]
H. Jin et al., "Identification of SPP1+ macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics," Frontiers in Immunology, vol. 15, 2024.
[13]
W. Kim et al., "Characterization of an in vitro steatosis model simulating activated de novo lipogenesis in MAFLD patients," iScience, vol. 26, no. 10, 2023.
[14]
B. Yulug et al., "Combined metabolic activators improve cognitive functions in Alzheimer's disease patients : a randomised, double-blinded, placebo-controlled phase-II trial," Translational Neurodegeneration, vol. 12, no. 1, 2023.
[15]
U. M. Battisti et al., "Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase," Nutrients, vol. 15, no. 3, pp. 577, 2023.
[16]
H. Yang et al., "Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators," Free Radical Biology & Medicine, vol. 204, pp. 347-358, 2023.
[17]
M. G. S. Rutten et al., "Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia," Cancer & Metabolism, vol. 11, no. 1, 2023.
[18]
H. Turkez et al., "RETRACTED: Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases," Life Sciences, vol. 314, 2023.
[19]
H. Jin et al., "Systematic transcriptional analysis of human cell lines for gene expression landscape and tumor representation," Nature Communications, vol. 14, no. 1, pp. 5417, 2023.
[20]
X. Li et al., "The acute effect of different NAD+ precursors included in the combined metabolic activators," Free Radical Biology & Medicine, vol. 205, pp. 77-89, 2023.
[21]
R. K. Baboota et al., "BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH," Nature Metabolism, vol. 4, no. 8, pp. 1007-1021, 2022.
[22]
C. Zhang et al., "Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning," EBioMedicine, vol. 83, 2022.
[23]
A. T. Ambikan et al., "Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity," Cell Systems, vol. 13, no. 8, pp. 665-681.e4, 2022.
[24]
M. Zeybel et al., "Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis," Advanced Science, vol. 9, no. 11, pp. 2104373, 2022.
[25]
X. Li et al., "Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach," EBioMedicine, vol. 78, pp. 103963, 2022.
[26]
H. Yang et al., "A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic liver disease," iScience, vol. 24, no. 11, 2021.
[27]
Ö. Altay et al., "Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19," Advanced Science, vol. 8, no. 17, 2021.
[28]
H. Yang et al., "Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet," Biomedicines, vol. 9, no. 10, 2021.
[29]
M. Zeybel et al., "Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients," Molecular Systems Biology, vol. 17, no. 10, 2021.
Non-peer reviewed
Articles
[30]
H. Yang et al., "Revisiting the role of serine metabolism in hepatic lipogenesis," Nature Metabolism, vol. 5, no. 5, pp. 760-761, 2023.
Theses
[31]
H. Yang, "Integrated understanding and targeting metabolic dysregulation in chronic liver disease : A multi-omics and systems biology perspective," Doctoral thesis Stockholm : KTH Royal Institute of Technology, TRITA-CBH-FOU, 2024:25, 2024.
Other
[32]
[33]
[34]
H. Yang et al., "Integrative proteo-transcriptomic characterization of advanced fibrosis in chronic liver disease across etiologies," (Manuscript).
[35]
M. Yuan et al., "The Emerging Significance of PKLR in Liver Metabolism : A Comprehensive Review," (Manuscript).
[36]
M. Yuan et al., "The Human Pathology Atlas for deciphering the prognostic features of human cancers," (Manuscript).
Latest sync with DiVA:
2025-10-11 23:01:11 UTC